STAT+: AstraZeneca opens new Boston site
AstraZeneca opened a new R&D site in Kendall Square yesterday, celebrating a $1 billion investment in the unsettled center of U.S. biotechnology after a spate of Chinese dealmaking.
AstraZeneca has announced the opening of a new facility in Boston, marking an expansion of its presence in the United States. The company's decision to establish this site underscores its commitment to growing its research and development capabilities in the region. While specific details regarding the purpose and scale of the new Boston location have not been disclosed, the move is expected to bolster AstraZeneca's efforts in advancing medical innovations.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
